Biomarker predictive of NSCLC response to drug
Monday, May 1, 2017 - 09:32
in Health & Medicine
Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression-free survival.